

# Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting

2/28/2019

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced seven presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019 in Atlanta, Georgia.

## Details of Arcus's Presentations are as follows:

### ORAL PRESENTATION:

#### AB680 (small-molecule CD73 inhibitor)

**Title:** Development of potent and selective CD73 inhibitors: Discovery and characterization of AB680

**Date and Time:** Saturday, March 30, 2019, 9:30 AM - 9:55 AM

**Location:** Room A311

### POSTER PRESENTATIONS:

#### AB928 (dual A<sub>2a</sub> R/A<sub>2b</sub> R antagonist)

**Title:** Methods for assessment of the "adenosine fingerprint" in clinical trials of AB928

**Abstract Number:** 3168

**Date and Time:** Tuesday, April 2, 2019, 8:00 AM - 12:00 PM

**Location:** Exhibit Hall B, Poster Section: 21, Poster Board Number: 21

**Title:** Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers

**Abstract Number:** 4980

**Date and Time:** Wednesday, April 3, 2019, 8:00 AM - 12:00 PM

**Location:** Exhibit Hall B, Poster Section: 24, Poster Board Number: 3

AB122 (anti-PD-1 antibody)

**Title:** Longitudinal monitoring of neoepitope-specific T cell repertoires in patient blood following cancer immunotherapy

**Abstract Number:** 4042

**Date and Time:** Tuesday, April 2, 2019, 1:00 PM - 5:00 PM

**Location:** Exhibit Hall B, Poster Section: 22, Poster Board Number: 5

**Title:** Receptor occupancy and neo-epitope specific T-cell repertoires in patients with solid tissue tumors following anti-PD-1 therapy

**Abstract Number:** 4100

**Session Date and Time:** Tuesday, April 2, 2019, 1:00 PM - 5:00 PM

**Location:** Exhibit Hall B, Poster Section: 24, Poster Board Number: 3

AB154 (anti-TIGIT antibody)

**Title:** Characterization of AB154, a humanized  $\alpha$ -TIGIT antibody, for use in combination therapies

**Abstract Number:** 1557

**Session Date and Time:** Monday, April 1, 2019, 8:00 AM - 12:00 PM

**Location:** Exhibit Hall B, Poster Section: 25, Poster Board Number: 26

AB474 (arginase inhibitor)

**Title:** AB474, a potent orally bioavailable inhibitor of arginase, for the treatment of cancer

**Abstract Number:** 3862

**Date and Time:** Tuesday, April 2, 2019, 1:00 PM - 5:00 PM

**Location:** Exhibit Hall B, Poster Section: 12, Poster Board Number: 12

## About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus's other product candidates. Arcus's other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small-molecule inhibitor of CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit [www.arcusbio.com](http://www.arcusbio.com).

Source: Arcus Biosciences

View source version on [businesswire.com](https://www.businesswire.com/news/home/20190228005221/en/): <https://www.businesswire.com/news/home/20190228005221/en/>

Nicole Arndt

(510) 284-4728

[narndt@arcusbio.com](mailto:narndt@arcusbio.com)

Source: Arcus Biosciences, Inc.